glp 1 drugs and parkinson's disease Neuroprotective effects of GLP-1 class in Repurposing GLP-1 Receptor Agonists for
Description
Sellam, J
Non-Pharmaceutical Options Lifestyle interventions Structured diet plans, regular physical activity, and behavioural therapy
Many people with IBS-C experience symptoms associated with slower or more difficult bowel movement pattern
At 40 weeks, a significant reduction in HbA1c proportional to the dosage of the drug used was observed (-1.87% with 5 mg of tirzepatide, -1.89% with 20 mg of tirzepatide, and -2.07% with 15 mg of tirzepatide versus +0.04% with the placebo)
153 MaliniNARoy GeorgeK
